CD73-targeted 68Ga PET/CT imaging to detect malignant brain tumors
Official title: Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
Run by Peking Union Medical College Hospital · NCT07023640 · Data updated 2026-11-12
This imaging test will try to show whether CD73-targeted 68Ga-DOTA-mPNE PET/CT can detect and characterize malignant brain tumors in adults with suspected or confirmed disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | July 10, 2025 |
| Main results expected | June 17, 2026 |
| Study ends | June 17, 2026 |
| Registry record updated | August 5, 2025 |
| Trial ID | NCT07023640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18 years) with suspected or confirmed malignant brain tumors who have at least one measurable lesion, are treatment‑naive to radiotherapy/chemotherapy, and can undergo PET/CT and planned biopsy or surgery.
✕Probably not a fit
Patients with severe hepatic or renal dysfunction, pregnant or breastfeeding individuals, those unable to lie flat or with severe claustrophobia, or patients without measurable lesions or unwilling to undergo required procedures are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with clinically suspected or confirmed malignant brain tumors will receive a single injection of the CD73-targeted radiotracer 68Ga-DOTA-mPNE and undergo PET/CT imaging to measure tracer uptake in target lesions. In a subgroup of up to 10 participants, dynamic PET/CT imaging will be performed for up to 90 minutes after injection to characterize biodistribution and pharmacokinetics. Imaging findings will be correlated with pathology, immunohistochemistry, and molecular markers when tissue is available to determine how tracer uptake relates to CD73 expression. The protocol excludes patients with severe organ dysfunction, pregnancy, or inability to undergo imaging procedures, and requires measurable lesions per RECIST 1.1 and willingness to undergo biopsy or surgery when indicated.
Why it matters
Potential benefit: If successful, this method could provide a noninvasive molecular imaging marker of CD73 expression to improve diagnosis, lesion characterization, and help guide treatment decisions for brain malignancies.
How similar studies have gone: CD73-targeted imaging in humans is relatively novel with limited published data, although other 68Ga-labeled PET tracers have previously shown promise for tumor detection and characterization.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years, with an expected survival of ≥12 weeks. 2. No prior radiotherapy or chemotherapy; eligible for surgery or biopsy to obtain pathological diagnosis. 3. At least one measurable target lesion according to RECIST version 1.1 (Response Evaluation Criteria in Solid Tumors). 4. Written informed consent obtained and able to comply with follow-up requirements. Exclusion Criteria: 1. Severe hepatic or renal dysfunction. 2. Women who are planning to conceive, currently pregnant, breastfeeding, or intend to have children during the study period are not eligible. Fertile participants must use effective contraception during the study. 3. Unable to lie flat for 30 minutes. 4. Refusal to participate in this clinical study. 5. Claustrophobia or other psychiatric disorders. 6. Any other condition deemed unsuitable for study participation by the investigator.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Xianzhong Zhang, PhD — Peking Union Medical College Hospital
- Study coordinator: Chenhao Jia, M.D.
- Email: jiachenhao24@163.com
- Phone: 18548703382
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
-
Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases
This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.